Von Willebrand factor linked to bleeding complications

Von willebrand factor linked to bleeding complications

(HealthDay) -- Oral anticoagulation (OAC)-treated patients with high levels of von Willebrand factor (VWF) have elevated risks of bleeding complications and cardiovascular and all-cause mortality, according to a study published in the March issue of the Journal of Internal Medicine.

Marcus Lind, M.D., of Umeå University Hospital in Sweden, and associates conducted a longitudinal study of 719 receiving OAC treatment to evaluate the link between VWF plasma levels and risk of bleeding complications, cardiovascular death, and all-cause mortality.

During 4.2 years of follow-up, the researchers identified 113 cases of clinically relevant bleeding and 73 cases of major bleeding; and there were 161 deaths, including 110 attributed to cardiovascular disease. There was a significantly increased risk of bleeding complications for patients in the highest tertile of VWF (hazard ratio [HR] for major bleeding, 2.53; HR for clinically relevant bleeding, 2.19). VWF was significantly associated with cardiovascular and all-cause mortality (HR, 1.68 and 1.77, respectively). These findings were significant after adjusting for age, high-sensitivity C-reactive protein, and creatinine.

"Our findings imply that the use of VWF as a risk marker for thromboembolic events is complicated by the association of VWF with ," the authors write.


Explore further

New study shows patients with coronary artery disease

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Journal of Internal Medicine

Copyright © 2012 HealthDay. All rights reserved.

Citation: Von Willebrand factor linked to bleeding complications (2012, March 9) retrieved 1 June 2020 from https://medicalxpress.com/news/2012-03-von-willebrand-factor-linked-complications.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments